

OPWG Melanoma Subgroup Selected Literature for Review

1. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation.

Smedley RC, Spangler WL, Esplin DG, Kitchell BE, Bergman PJ, Ho HY, Bergin IL, Kiupel M. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. *Vet Pathol.* 2011 Jan;48(1):54-72.

2. Cell proliferation and expression of connexins differ in melanotic and amelanotic canine oral melanomas.

Teixeira TF, Gentile LB, da Silva TC, Mennecier G, Chaible LM, Cogliati B, Roman MA, Gioso MA, Dagli ML. Cell proliferation and expression of connexins differ in melanotic and amelanotic canine oral melanomas. *Vet Res Commun.* 2014 Mar;38(1):29-38.

3. Canine melanoma diagnosis: RACK1 as a potential biological marker.

Campagne C, Julé S, Alleaume C, Bernex F, Ezagal J, Château-Joubert S, Estrada M, Aubin-Houzelstein G, Panthier JJ, Egidy G. Canine melanoma diagnosis: RACK1 as a potential biological marker. *Vet Pathol.* 2013 Nov;50(6):1083-90.

4. Alteration in E-cadherin/ β -catenin expression in canine melanotic tumors.

Han JI, Kim Y, Kim DY, Na KJ. Alteration in E-cadherin/ β -catenin expression in canine melanotic tumors. *Vet Pathol.* 2013 Mar;50(2):274-80.

5. Canine cutaneous melanocytic tumours: significance of β -catenin and survivin immunohistochemical expression.

Bongiovanni L, D'Andrea A, Porcellato I, Ciccarelli A, Malatesta D, Romanucci M, Della Salda L, Mechelli L, Brachelente C. Canine cutaneous melanocytic tumours: significance of β -catenin and survivin immunohistochemical expression. *Vet Dermatol.* 2015 Aug;26(4):270-e59. doi: 10.1111/vde.12211. Epub 2015 May 12.

6. Profiling of plasma metabolites in canine oral melanoma using gas chromatography-mass spectrometry.

Kawabe M, Baba Y, Tamai R, Yamamoto R, Komori M, Mori T, Takenaka S. Profiling of plasma metabolites in canine oral melanoma using gas chromatography-mass spectrometry. *J Vet Med Sci.* 2015 Apr 4. [Epub ahead of print]

7. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas.

Murakami A, Mori T, Sakai H, Murakami M, Yanai T, Hoshino Y, Maruo K. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. *Vet Comp Oncol.* 2011 Sep;9(3):219-24.

8. Study of c-kit immunoexpression in canine cutaneous melanocytic tumors.

Gomes J, Queiroga FL, Prada J, Pires I. Study of c-kit immunoexpression in canine cutaneous melanocytic tumors. *Melanoma Res.* 2012 Jun;22(3):195-201.

9. Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998-2011).

Tuohy JL, Selmic LE, Worley DR, Ehrhart NP, Withrow SJ. Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998-2011). *J Am Vet Med Assoc.* 2014 Dec 1;245(11):1266-73.

10. Results of surgical excision and evaluation of factors associated with survival time in dogs with lingual neoplasia: 97 cases (1995-2008).

Culp WT, Ehrhart N, Withrow SJ, Rebhun RB, Boston S, Buracco P, Reiter AM, Schallberger SP, Aldridge CF, Kent MS, Mayhew PD, Brown DC. Results of surgical excision and evaluation of factors associated with survival time in dogs with lingual neoplasia: 97 cases (1995-2008). *J Am Vet Med Assoc.* 2013 May 15;242(10):1392-7.

11. Detection of novel polymorphisms in the ckit gene of canine patients with lymphoma, melanoma, haemangiosarcoma, and osteosarcoma.

Gramer I, Kessler M, Geyer J. *Vet Res Commun.* 2016 Mar 12. [Epub ahead of print]

12. PDGFRs expression in dogs affected by malignant oral melanomas: correlation with prognosis.

Iussich S, Maniscalco L, Di Sciuva A, Iotti B, Morello E, Martano M, Gattino F, Buracco P, De Maria R. *Vet Comp Oncol.* 2016 Feb 1. doi: 10.1111/vco.12190. [Epub ahead of print]

13. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma.

Treggiari E, Grant JP, North SM. *J Vet Med Sci.* 2016 Jan 15. [Epub ahead of print]

14. Safety of administering the canine melanoma DNA vaccine (Oncept) to cats with malignant melanoma - a retrospective study.

Sarbu L, Kitchell BE, Bergman PJ. *J Feline Med Surg.* 2015 Dec 18. pii: 1098612X15623319. [Epub ahead of print]

15. Accuracy of routine cytology and immunocytochemistry in preoperative diagnosis of oral amelanotic melanomas in dogs.

Przeździecki R, Czopowicz M, Sapieryński R. *Vet Clin Pathol.* 2015 Dec;44(4):597-604. doi: 10.1111/vcp.12292. Epub 2015 Sep 23.

16. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.

Paoloni M, Mazcko C, Selting K, Lana S, Barber L, Phillips J, Skorupski K, Vail D, Wilson H, Biller B, Avery A, Kiupel M, LeBlanc A, Bernhardt A, Brunkhorst B, Tighe R,

Khanna C. PLoS One. 2015 Jun 19;10(6):e0129954. doi: 10.1371/journal.pone.0129954. eCollection 2015.

17. Canine cutaneous melanocytic tumours: significance of β -catenin and survivin immunohistochemical expression.

Bongiovanni L, D'Andrea A, Porcellato I, Ciccarelli A, Malatesta D, Romanucci M, Della Salda L, Mechelli L, Brachelente C. Vet Dermatol. 2015 Aug;26(4):270-e59. doi: 10.1111/vde.12211. Epub 2015 May 12.

18. Cytokine-Enhanced Vaccine and Interferon- β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.

Finocchiaro LM, Fondello C, Gil-Cardeza ML, Rossi ÚA, Villaverde MS, Riveros MD, Glikin GC. Hum Gene Ther. 2015 Jun;26(6):367-76. doi: 10.1089/hum.2014.130. Epub 2015 May 26.

19. Clinical systemic lupeol administration for canine oral malignant melanoma.

Yokoe I, Azuma K, Hata K, Mukaiyama T, Goto T, Tsuka T, Imagawa T, Itoh N, Murahata Y, Osaki T, Minami S, Okamoto Y. Mol Clin Oncol. 2015 Jan;3(1):89-92. Epub 2014 Oct 30.

20. Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma.

Cancedda S, Rohrer Bley C, Aresu L, Dacasto M, Leone VF, Pizzoni S, Gracis M, Marconato L. Vet Comp Oncol. 2014 Nov 10. doi: 10.1111/vco.12122. [Epub ahead of print]

21. Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001-2012).

Boston SE, Lu X, Culp WT, Montinaro V, Romanelli G, Dudley RM, Liptak JM, Mestrinho LA, Buracco P. J Am Vet Med Assoc. 2014 Aug 15;245(4):401-7. doi: 10.2460/javma.245.4.401.

22. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.

Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M, De Maria R, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, Zabarino S, Ferrone S, Buracco P, Cavallo F. Clin Cancer Res. 2014 Jul 15;20(14):3753-62. doi: 10.1158/1078-0432.CCR-13-3042. Epub 2014 May 29.

23. Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma.

Simpson RM, Bastian BC, Michael HT, Webster JD, Prasad ML, Conway CM, Prieto VM, Gary JM, Goldschmidt MH, Esplin DG, Smedley RC, Piris A, Meuten DJ, Kiupel M, Lee CC, Ward JM, Dwyer JE, Davis BJ, Anver MR, Molinolo AA, Hoover SB, Rodriguez-Canales J, Hewitt SM. *Pigment Cell Melanoma Res.* 2014 Jan;27(1):37-47. doi: 10.1111/pcmr.12185. Epub 2013 Nov 21.

24. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma.

Ottnod JM, Smedley RC, Walshaw R, Hauptman JG, Kiupel M, Obradovich JE. *Vet Comp Oncol.* 2013 Sep;11(3):219-29. doi: 10.1111/vco.12057.

25. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.

Fowles JS, Denton CL, Gustafson DL. *Vet Comp Oncol.* 2015 Sep;13(3):288-304. doi: 10.1111/vco.12044. Epub 2013 Jun 7.